![]() 3 About Anoro ElliptaĪnoro Ellipta is a combination long-acting muscarinic antagonist (LAMA) (also known as an anticholinergic) / long-acting beta 2-adrenergic agonist (LABA). Most people who have COPD are at least 40 years old when symptoms begin. Cigarette smoke, breathing in second hand smoke, air pollution, chemical fumes or dust from the environment or workplace can all contribute to COPD. Long-term exposure to lung irritants that damage the lungs and the airways are usually the cause of COPD. COPD is thought to affect 4-10% of the adult population in Europe. COPD is characterised by obstruction to airflow that interferes with normal breathing. About COPDĬOPD is a disease of the lungs that includes chronic bronchitis, emphysema or both. A total of 905 patients with COPD were randomized 1:1 to UMEC/VI 62.5/25mcg inhalation powder or tiotropium 18mcg. This study was a 24-week, blinded, parallel group, multicenter study to assess the efficacy and safety of UMEC/VI 62.5/25mcg inhalation powder administered once-daily in the dry powder inhaler, Ellipta ®, compared to tiotropium 18mcg administered once-daily in the HandiHaler ® inhaler. These data were previously announced in July 2012. UMEC/VI previously demonstrated statistically significant improvements in trough FEV 1 compared with tiotropium in an earlier six-month active-comparator study (DB2113360), and numerically greater (although not statistically significant) improvements from tiotropium in another (DB2113374). Aguiar, President and Chief Executive Officer of Theravance, said: “We believe the results from this positive study will provide physicians with additional useful data regarding the potential benefits of Anoro Ellipta as a treatment option for appropriate patients with COPD.” We hope the publication will inform physicians as they consider which treatment option is best to meet their individual patient’s needs.” These results support the lung function benefit of Anoro Ellipta in the treatment of appropriate patients with COPD. The incidence of any on-treatment serious adverse event in both treatment arms was 4%.ĭarrell Baker, SVP and Head, Global Respiratory Franchise, GSK said: “We are pleased to announce the publication of these important data comparing Anoro Ellipta with tiotropium. The overall incidence of on-treatment adverse events was 44% in the UMEC/VI group and 42% in the tiotropium group. The most commonly reported side effects for both UMEC/VI and tiotropium included headache (9% UMEC/VI 7% tiotropium), nasopharyngitis (6% UMEC/VI 7% tiotropium), cough (3% UMEC/VI 3% tiotropium) and back pain (2% UMEC/VI 3% tiotropium). In this study UMEC/VI 62.5/25 mcg showed a statistically significant improvement of 112mL compared with tiotropium 18mcg (95% confidence interval (CI) 81, 144, p<0.001) for the primary endpoint measurement of lung function using trough forced expiratory volume in one second (FEV 1) at the end of the treatment period (day 169).įor the secondary endpoint measurement of lung function using weighted mean FEV 1 0 – 6 hour, at the end of the treatment period (day 168) UMEC/VI 62.5/25mcg showed a statistically significant improvement of 105mL, (95% confidence interval (CI) 71, 140, p<0.001) compared to tiotropium 18 mcg. Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro ® Ellipta ® (umeclidinium /vilanterol, ‘UMEC/VI’), the combination long-acting muscarinic antagonist (LAMA) / long-acting beta 2-adrenergic agonist (LABA), with the LAMA tiotropium, administered in the HandiHaler ® inhaler, in patients with chronic obstructive pulmonary disease (COPD). (accessed 7 October 2015).Issued: London, UK and South San Francisco, CA, USA Indacaterol with glycopyrronium (Ultibro Breezhaler) for chronic obstructive pulmonary disease. July 2015 PBAC Outcomes \u2013 Positive Recommendations, 2015. Australian Government Department of Health.Respimat PI.pdf (accessed 7 October 2015). Product Information \u2013 Spiolto Respimat 2015. Product Information \u2013 Brimica Genuair. Public Summary Document \u2013 tiotropium bromide and olodaterol hydrochloride. Public Summary Document \u2013 Aclidinium bromide and eformoterol fumarate dihydrate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |